Researchers performed a cross-sectional analysis of private payer–specific negotiated prices for therapies at National Cancer Institute-designated cancer centers from April 1 to Oct. 15, 2021. They also determined whether each center participated in the federal 340B drug-pricing program, which allows the purchase of discounted outpatient drugs, and the 25 parenteral cancer therapies by Medicare Part B spending in 2019.
Price markups for each cancer therapy were calculated as the difference between payer-specific prices and estimated acquisition costs.
Four findings:
- Of the 61 National Cancer Institute-designated cancer centers included in the study, 27 disclosed private payer-specific prices for at least one popular cancer therapy.
- Median drug price markups at all centers and payers ranged from 118.4 percent and 633.6 percent.
- Across-center price ratios, the ratio between the 90th percentile and 10th percentile median prices across centers, ranged between 2.2 and 15.8.
- Median within-center price ratios, the ratio between the 90th percentile and 10th percentile prices between payers, ranged from 1.8 to 2.5.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
